Use this URL to cite or link to this record in EThOS:
Title: A novel approach to prostate cancer gene therapy: tageting neurotensin receptors with baculovirus.
Author: Swift, Stephanie L.
ISNI:       0000 0001 3494 2192
Awarding Body: York
Current Institution: University of York
Date of Award: 2008
Availability of Full Text:
Full text unavailable from EThOS.
Please contact the current institution’s library for further details.
Prostate cancer is now the most commonly diagnosed male malignancy in the United Kingdom. Traditional treatments provide only temporary resolution of disease, with a more aggressive, androgen-independent form recurring after 18-20 months of initial therapy, which is very difficult to treat. This recurrence is thought to result from targeting the bulk of the tumour, the differentiated daughter cells, but not the prostate cancer stem cell initiator of disease. Novel treatments, such as gene therapy, that have the capacity to target multiple cell types, have the potential to provide much improved results. Cell surface proteins that are overexpressed on malignant prostate cells compared to benign counterparts can be exploited in the transductional targeting of gene therapy vectors. In advanced, androgen-independent prostate cancer. experimental evidence suggests that neurotensin receptors (NTRs) are recruited as an alternative pathway to enable tumour growth in the absence of androgens.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID:  DOI: Not available